Kazia Therapeutics Ltd ADR (KZIA)

NASDAQ
Currency in USD
3.5900
+0.1900(+5.59%)
Closed·
After Hours
3.6900+0.1000(+2.7855%)
·
KZIA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KZIA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.45003.5900
52 wk Range
2.860079.0000
Key Statistics
Edit
Prev. Close
3.4
Open
3.45
Day's Range
3.45-3.59
52 wk Range
2.86-79
Volume
8.58K
Average Vol. (3m)
42.95K
1-Year Change
-74.56%
Book Value / Share
-11.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KZIA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.0243
Upside
+318.51%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year
Show more

Kazia Therapeutics Ltd ADR Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Compare KZIA to Peers and Sector

Metrics to compare
KZIA
Peers
Sector
Relationship
P/E Ratio
−0.2x−4.6x−0.5x
PEG Ratio
−0.03−0.110.00
Price / Book
−0.6x2.9x2.6x
Price / LTM Sales
2.5x8.7x3.0x
Upside (Analyst Target)
318.6%177.5%53.7%
Fair Value Upside
Unlock4.6%8.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.0243
(+318.51% Upside)

Earnings

Latest Release
Nov 15, 2024
EPS / Forecast
-31.22 / --
Revenue / Forecast
2.48M / --
EPS Revisions
Last 90 days

People Also Watch

0.067
AGMH
+11.67%
2.100
TGL
+15.38%
0.078
AWHL
0.00%
0.1778
BTOG
-1.28%
6.4737
LICN
+21.92%

FAQ

What Is the Kazia Therapeutics ADR (KZIA) Stock Price Today?

The Kazia Therapeutics ADR stock price today is 3.59

What Stock Exchange Does Kazia Therapeutics ADR Trade On?

Kazia Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kazia Therapeutics ADR?

The stock symbol for Kazia Therapeutics ADR is "KZIA."

What Is the Kazia Therapeutics ADR Market Cap?

As of today, Kazia Therapeutics ADR market cap is 4.01M.

What Is Kazia Therapeutics ADR's Earnings Per Share (TTM)?

The Kazia Therapeutics ADR EPS (TTM) is -50.78.

From a Technical Analysis Perspective, Is KZIA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.